plain language summaries

On 17–18 October, more than a hundred patients, patient advocates and representatives from pharma gathered in London, UK, for the 13th Annual eyeforpharma Patient Summit Europe to discuss the importance of patient centricity in the pharmaceutical industry.

Oxford PharmaGenesis was delighted to attend the Medical Affairs Leaders Forum in London, UK on 18–20 October. This meeting brought together medical affairs professionals and related industry staff and academics from Europe and beyond for 3 days of presentations, discussions and networking.

14­–17 September 2016, London, UK These are exciting times in the field of multiple sclerosis (MS) management; the past 5 years have seen an explosion in the number of disease-modifying therapies (DMTs) licensed for the treatment of patients with relapsing–remitting MS (RRMS).

The 2016 Medical Affairs Strategic Summit (MASS) West began on 14 September in San Diego, California, USA. The 3-day summit hosted professionals involved in all aspects of medical affairs including clinical research, health economics, key opinion leadership, medical communications and publication planning.

Oxford PharmaGenesis insights into patient-reported outcomes (PROs), health literacy and patient-centricity were the subject of the September edition of the International Society for Medical Publication Professionals (ISMPP) online education series, ISMPP University (ISMPP U).

Today, the Right Honourable Edward Vaizey, local MP for Wantage, visited award-winning HealthScience communications consultancy Oxford PharmaGenesis to discuss the implications of Brexit for trade, education, research and health funding in Oxfordshire.

We are delighted to announce that Sorcha Bangham has joined Oxford PharmaGenesis as our Learning and Development Manager.

A simple scoring system can predict the chances of children with a respiratory tract infection being admitted to hospital, thereby helping to target antibiotics more appropriately. This important finding is highlighted in a commentary written by Chris Winchester, Managing Director of Oxford PharmaGenesis, and colleagues, which is published today in Lancet Respiratory Medicine.